Thomas Taapken has been named chief financial officer of Epigenomics, the Berlin-based company said this week.
Taapken will succeed outgoing CFO Oliver Schacht on April 1. Taapken joins Epigenomics from Biotie Therapies, where he currently serves as CFO. He previously was CFO of Elbion from 2005 until it merged with Biotie in 2008. Before that, he was an investment partner at DVC Deutsche Venture Capital from 2003 to 2005 and San Francisco-based US venture capital firm Burrill & Company from 1998 to 2002.
Genome British Columbia has appointed Brad Popovich to be its chief scientific officer. In the role, he will manage genomics, bioinformatics, and proteomics, as well as scientists and partnerships. Popovich recently was president and CEO of Sirius Genomics, and before that he was vice president of operations at Xenon Pharmaceuticals. He also has headed the molecular diagnostics lab at Oregon Health Sciences University.